Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: PLB1004; Drug: Pemetrexed+ （carboplatin or Cisplatin）with or without Sintilimab Sponsors: Avistone Biotechnology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials